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subjects. Proteomic data, filtered for FC >2, detected 2051 spots
with 1899 (92.5%) being equally oxidised between NT and HT.
In addition, oxidation of 57 (2.9%) spots was increased, while
95 (4.6%) were decreased in HT. Candidate proteins exhibiting
consistent changes across three experimental replicates included
b-actin (FC = –2.86), annexin A1 (–2.23), galectin-1 (–1.67),
FK506 binding protein (–2.35) and polymerase I and transcript
release factor (PTRF, –1.92). Stimulation with AngII altered the
redox status in 2–3% of proteins, both in HT and NT. However,
vimentin was the only target changing consistently across the
replicates (FC = 2.48). Our findings indicate that pro-hyperten-
sive agents may not impact significantly on irreversible protein
and PTP oxidation in health and disease, but may have effects
on reversible oxidation. Our proteomic data, in agreement with
our previous rat studies, support decreased reversible thiol oxi-
dation in hypertension.
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It is well established that vascular calcification is a common com-
plication in diabetes and recent studies suggest that glycation
may play a pathogenic role in this process. The aim of this study
was to investigate the role of glycation in the induction of calci-
fication in vascular smooth muscle cells (SMCs), and the poten-
tial inhibitory effects of the anti-diabetic agent, Momordica
Charantia. Vascular SMCs were incubated with native or gly-
cated LDL in the presence of osteogenic media and mineral dep-
osition was determined using alizarin red staining and alkaline
phosphatase (ALP) activity. We found that SMCs incubated in
osteogenic media exhibited mineralisation after 7 days. This cal-
cification was significantly increased following treatment with
glycated-LDL, but not by native LDL. Furthermore, we found
that ALP activity was significantly elevated at day 4 in glycated-
LDL treated cells, compared to those incubated in native LDL.
The vascular SMCs were exposed to increasing concentrations
of Momordica Charantia extract in the presence of osteogenic
media. ALP activity was reduced in treated cells, compared to
osteogenic controls. Furthermore, we found that Momordica
Charantia reduced gene expression of a range of biomarkers
linked with vascular calcification after 4 days in a dose-depend-
ent manner, including osteocalcin and BMP-2. In conclusion, we
have shown that glycated LDL promotes osteogenic differentia-
tion of vascular SMCs. Momordica Charantia extract shows
promise as a potential therapeutic agent to reduce vascular calci-
fication. Future work will identify the active ingredient responsi-
ble for calcification inhibitory effects, and establish whether it
links to the pathological glycation-induced osteogenesis.
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Glycomimetics are molecules that mimic the structure of carbo-
hydrates involved in important biological processes. Small mole-
cule glycomimetics are an untapped source of novel therapies
for endothelial dysfunction, a hallmark of cardiovascular compli-
cations associated with diabetes. The current study aims to inves-
tigate the possible protective effects of newly synthesised small
molecule glycomimetics against lipid-induced endothelial dys-
function, with an emphasis on nitric oxide (NO) and induced
oxidative stress. Glycomimetics were synthesised by the stepwise
transformation of 2,5-dihydroxybenzoic acid to a range of 2,5-
substituted benzoic acid derivatives incorporating the key sulfate
groups to mimic the interactions of heparan sulfate. Acetylcho-
line-induced endothelium-dependent relaxation in mouse thora-
cic aortic rings was measured using wire myography, and human
umbilical vein endothelial cells (HUVECs) function was assessed
in the presence or absence of palmitate, with or without the test
glycomimetics. NO and reactive oxygen species (ROS) produc-
tion was measured using DAF-2 and H2DCF-DA, respectively.
Colorimetric assays were used to determine lipid peroxidation
and activity of the antioxidant enzymes. Expression of Akt,
eNOS, Nrf-2, NQO-1 and HO-1 were assessed using RT-PCR
and western blotting. At 1 mM concentration, the synthesised
glycomimetics significantly improved endothelium-dependent
relaxation ex vivo and protected HUVECs against palmitate-
induced oxidative stress and reduced NO production. Pre-incu-
bation of HUVECs with all compounds upregulated Akt/eNOS
signalling, activated Nrf2/ARE pathway, and suppressed ROS-
induced lipid peroxidation. In conclusion, our newly synthesised
small molecule glycomimetics protect against lipid-induced endo-
thelial dysfunction. These novel cytoprotective effects open the
door to a new class of therapeutic drugs to target endothelial
dysfunction.
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